All In Biotech

Drug Trial Radar · NCT03322566

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 233 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

233

Actual

Start

Jan 9, 2018

Primary completion

Dec 13, 2018

Study completion Oct 16, 2020

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 26, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).

Conditions

  • Lung Cancer

Interventions

  • PembrolizumabDrug

    Pembrolizumab administered intravenously every 3 weeks.

  • EpacadostatDrug

    Epacadostat administered orally twice daily.

  • Platinum-based chemotherapyDrug

    Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.

  • PlaceboDrug

    Matching placebo administered orally twice daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) of Pembrolizumab + Chemotherapy + Epacadostat Versus Pembrolizumab + Chemotherapy + PlaceboTime frame: Assessed every 12 weeks up to 24 months

Locations

94 sites in 14 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center, PC

    Daphne, Alabama

  • Western Regional Medical Center, Inc.

    Goodyear, Arizona

  • Arizona Oncology Associates PC- HOPE

    Tucson, Arizona

  • Lynn Cancer Institute

    Boca Raton, Florida

  • Florida Cancer Specialists (South Region)

    Fort Myers, Florida

  • Florida Cancer Specialists (North Region)

    St. Petersburg, Florida

  • PPG-Oncology

    Fort Wayne, Indiana

  • University of Michigan

    Ann Arbor, Michigan

  • MMCORC

    Saint Louis Park, Minnesota

  • St. Vincent Healthcare Frontier Cancer Center

    Billings, Montana

  • New York Oncology Hematology P.C

    Albany, New York

  • Oncology Hematology Care, Inc.

    Cincinnati, Ohio

  • Southwestern Regional Medical Center, Inc.

    Tulsa, Oklahoma

  • St. Luke's Hospital - Anderson Campus

    Easton, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Tennessee Oncology, PLLC/The Sarah Cannon Research Institute

    Chattanooga, Tennessee

  • Tennessee Oncology, PLLC/The Sarah Cannon Research Institute

    Nashville, Tennessee

  • Texas Oncology-Denton South

    Denton, Texas

  • Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care

    Blacksburg, Virginia

  • Emily Couric Clinical Cancer Center

    Charlottesville, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia

  • The Crown Princess Mary Cancer Centre Westmead

    Westmead, New South Wales, Australia

  • Southern Medical Day Care Centre

    Wollongong, New South Wales, Australia

  • MNCCI Port Macquarie Base Hospital

    Port Macquarie, New South Wales (Australia), Australia

  • Cairns Base Hospital

    Cairns, Queensland, Australia

  • BCCA-Cancer Centre of the Southern Interior

    Kelowna, British Columbia, Canada

  • Lions Gate Hospital

    North Vancouver, British Columbia, Canada

  • CISSS de la Monteregie-Centre

    Greenfield Park, Quebec, Canada

  • CSSS de Laval- Hopital de la Cite de la Sante

    Laval, Quebec, Canada

  • CIUSSS Ouest de l'Ile - St-Mary's Hospital

    Montreal, Quebec, Canada

  • CIUSSS du Nord-de-l'ILe-de-Montreal Hopital du Sacre-Coeur de Montreal

    Montreal, Quebec, Canada

  • CHU de Quebec - Hotel-Dieu de Quebec

    Québec, Quebec, Canada

  • CIUSSS de la Mauricie-et-du-Centre-du-Quebec

    Trois-Rivières, Quebec, Canada

  • Orszagos Koranyi TBC es Pulmonologiai Intezet

    Budapest, Hungary

  • Veszprem Megyei Tudogyogyintezet

    Farkasgyepű, Hungary

  • Bekes Megyei Pandy Kalman Korhaz

    Gyula, Hungary

  • CRU Hungary Kft.

    Miskolc, Hungary

  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet

    Szolnok, Hungary

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.